| scholarly article | Q13442814 |
| P50 | author | Monika Rau | Q56985327 |
| Mathias Bähr | Q88133298 | ||
| Andreas Geier | Q90710992 | ||
| P2093 | author name string | Klaus Schulze-Osthoff | |
| Michael P Manns | |||
| Elmar Jaeckel | |||
| Heike Bantel | |||
| Joern M Schattenberg | |||
| Neele Stoeckmann | |||
| Stephanie Liebig | |||
| P2860 | cites work | Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany | Q57023805 |
| Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients | Q57735452 | ||
| The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD | Q61989968 | ||
| Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease | Q70886743 | ||
| Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis | Q73735584 | ||
| In situ monitoring of caspase activation in hepatobiliary diseases | Q74079797 | ||
| Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease | Q82648058 | ||
| Liver biopsy | Q83395480 | ||
| Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis | Q85084811 | ||
| Robust detection of liver steatosis and staging of NAFLD by an improved ELISA for serum cytokeratin-18 fragments | Q87056178 | ||
| Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease | Q87406034 | ||
| Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers | Q87445810 | ||
| Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study | Q24657221 | ||
| Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity | Q28297290 | ||
| Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 | ||
| Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis | Q30238749 | ||
| Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis | Q33867352 | ||
| Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. | Q34302040 | ||
| Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury | Q34359266 | ||
| Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. | Q34544284 | ||
| EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | Q34676840 | ||
| Apoptosis as a Mechanism for Liver Disease Progression | Q34764471 | ||
| An apoptosis panel for nonalcoholic steatohepatitis diagnosis | Q34995562 | ||
| Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. | Q35769495 | ||
| Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease | Q35893923 | ||
| Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease | Q36795373 | ||
| Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. | Q36967102 | ||
| Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients | Q37066731 | ||
| Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. | Q38070696 | ||
| A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver | Q38105838 | ||
| Noninvasive evaluation of NAFLD. | Q38141711 | ||
| Roles for chemokines in liver disease | Q38234487 | ||
| The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. | Q38676257 | ||
| Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Q38680300 | ||
| Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver. | Q38725581 | ||
| Apoptotic body engulfment by a human stellate cell line is profibrogenic. | Q40647924 | ||
| Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management | Q41725283 | ||
| Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up | Q42201783 | ||
| Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels | Q43183343 | ||
| Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis | Q44697151 | ||
| Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease | Q45066338 | ||
| Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis | Q45872331 | ||
| Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations | Q46078112 | ||
| Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis. | Q46566732 | ||
| Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease | Q48588687 | ||
| Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis | Q49797701 | ||
| The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. | Q50473358 | ||
| The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. | Q51089882 | ||
| [S2k Guideline non-alcoholic fatty liver disease]. | Q52864499 | ||
| P433 | issue | 8 | |
| P304 | page(s) | e00066 | |
| P577 | publication date | 2019-08-01 | |
| P1433 | published in | Clinical and translational gastroenterology | Q27723002 |
| P1476 | title | Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness | |
| P478 | volume | 10 |
Search more.